Evidence map›Paper›PMID 40677313›Full record

ArticleKidney international reports2025

Finerenone and Estimated GFR Slope in Type 2 Diabetes and CKD.

Masayuki Yamanouchi, Yuki Oba, Hisashi Kamido, Masatoshi Yoshimoto, Yusuke Yoshimura, Hisashi Sugimoto, Shigekazu Kurihara, Akinari Sekine, Tatsuya Suwabe, Naoki Sawa and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Masayuki YamanouchiNephrology Center, Toranomon Hospital, Tokyo, Japan.
Yuki ObaNephrology Center, Toranomon Hospital Kajigaya, Kanagawa, Japan.
Hisashi KamidoNephrology Center, Toranomon Hospital Kajigaya, Kanagawa, Japan.
Masatoshi YoshimotoNephrology Center, Toranomon Hospital Kajigaya, Kanagawa, Japan.
Yusuke YoshimuraNephrology Center, Toranomon Hospital Kajigaya, Kanagawa, Japan.
Hisashi SugimotoNephrology Center, Toranomon Hospital Kajigaya, Kanagawa, Japan.
Shigekazu KuriharaNephrology Center, Toranomon Hospital Kajigaya, Kanagawa, Japan.
Akinari SekineNephrology Center, Toranomon Hospital, Tokyo, Japan.
Tatsuya SuwabeNephrology Center, Toranomon Hospital, Tokyo, Japan.
Naoki SawaNephrology Center, Toranomon Hospital, Tokyo, Japan.
Takehiko WadaNephrology Center, Toranomon Hospital, Tokyo, Japan.
Kengo FuruichiDepartment of Nephrology, Kanazawa Medical University School of Medicine, Ishikawa, Japan.
Takashi WadaDepartment of Nephrology and Rheumatology, Kanazawa University, Ishikawa, Japan.
Yoshifumi UbaraNephrology Center, Toranomon Hospital, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

chronic kidney diseaseeGFR slopefinerenonenonsteroidal mineralocorticoid receptor (MR) antagonistreal-world studytype 2 diabetes mellitus

Identifiers

PMID40677313
PMCPMC12266157

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.